Item 9 Labs Corp (INLB)
0.0002
0.00 (0.00%)
USD |
OTCM |
May 02, 16:00
Item 9 Labs Cash from Financing (TTM): 2.321M for June 30, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
June 30, 2023 | 2.321M |
March 31, 2023 | 4.809M |
December 31, 2022 | 6.910M |
September 30, 2022 | 6.046M |
June 30, 2022 | 5.109M |
March 31, 2022 | 2.536M |
December 31, 2021 | 7.038M |
September 30, 2021 | 11.28M |
June 30, 2021 | 10.58M |
March 31, 2021 | 11.50M |
December 31, 2020 | 5.721M |
September 30, 2020 | 1.538M |
June 30, 2020 | 4.176M |
March 31, 2020 | 4.806M |
December 31, 2019 | 6.456M |
September 30, 2019 | 9.137M |
June 30, 2019 | 6.86M |
March 31, 2019 | 5.822M |
December 31, 2018 | 4.662M |
September 30, 2018 | |
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 |
Date | Value |
---|---|
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | 0.3247M |
June 30, 2016 | 0.4304M |
March 31, 2016 | 0.6271M |
December 31, 2015 | 0.551M |
September 30, 2015 | 0.7467M |
June 30, 2015 | 0.7079M |
March 31, 2015 | 0.7616M |
December 31, 2014 | 0.729M |
September 30, 2014 | 0.7772M |
June 30, 2014 | 0.6343M |
March 31, 2014 | 0.5203M |
December 31, 2013 | 0.7742M |
September 30, 2013 | 0.4076M |
June 30, 2013 | 0.4618M |
March 31, 2013 | 0.6423M |
December 31, 2012 | 0.3326M |
June 30, 2012 | -0.1584M |
March 31, 2012 | 0.2116M |
December 31, 2011 | 0.0401M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.538M
Minimum
Sep 2020
11.50M
Maximum
Mar 2021
6.284M
Average
6.046M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
Cantabio Pharmaceuticals Inc | 1.055M |
Q BioMed Inc | 0.8491M |
NVN Liquidation Inc | 19.55M |
Affymax Inc | -- |
Scopus BioPharma Inc | 2.217M |